Sökning: onr:"swepub:oai:gup.ub.gu.se/107026" > Comparative pharmac...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03003naa a2200397 4500 | |
001 | oai:gup.ub.gu.se/107026 | |
003 | SwePub | |
008 | 240910s2009 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1070262 URI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Eriksson, Bengt I.,d 1946u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xerben |
245 | 1 0 | a Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development |
264 | 1 | c 2009 |
520 | a For the past five decades, there has been little progress in the development of oral anticoagulants, with the choices being limited to the vitamin K antagonists (VKAs). The situation is changing with the development of orally active small molecules that directly target thrombin or activated factor X (FXa). The two agents in the most advanced stages of development are dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively. Both are approved in the EU and Canada for venous thromboprophylaxis in patients undergoing elective hip- or knee-replacement surgery. Other agents in the early stages of development include several FXa inhibitors (apixaban, DU 176b, LY 517717, YM 150, betrixaban, eribaxaban [PD 0348292] and TAK 442) and one thrombin inhibitor (AZD 0837). With a predictable anticoagulant response and low potential for drug-drug interactions, these new agents can be given in fixed doses without coagulation monitoring. This renders them more convenient than VKAs. While the anticoagulant effect of the new thrombin and FXa inhibitors is similar, differences in the pharmacokinetic and pharmacodynamic parameters may influence their use in clinical practice. Here, we compare the pharmacokinetic and pharmacodynamic features of these new oral agents. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
653 | a Animals | |
653 | a Antithrombin III/*pharmacokinetics/*pharmacology | |
653 | a Benzimidazoles/pharmacokinetics/pharmacology | |
653 | a Drug Discovery | |
653 | a Humans | |
653 | a Morpholines/pharmacokinetics/pharmacology | |
653 | a Pyrazoles/pharmacokinetics/pharmacology | |
653 | a Pyridines/pharmacokinetics/pharmacology | |
653 | a Pyridones/pharmacokinetics/pharmacology | |
653 | a Thiophenes/pharmacokinetics/pharmacology | |
653 | a Thrombin/*antagonists & inhibitors | |
700 | 1 | a Quinlan, D. J.4 aut |
700 | 1 | a Weitz, J. I.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org |
773 | 0 | t Clin Pharmacokinetg 48:1, s. 1-22q 48:1<1-22x 0312-5963 |
856 | 4 8 | u https://gup.ub.gu.se/publication/107026 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy